Benign Prostatic Hyperplasia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Boehringer Ingelheim, Merck & Co. Inc., Allergan PLC

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Benign Prostatic Hyperplasia pipeline constitutes 7+ key companies continuously working towards developing 8+ Benign Prostatic Hyperplasia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Benign Prostatic Hyperplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Benign Prostatic Hyperplasia Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Benign Prostatic Hyperplasia Market.

Some of the key takeaways from the Benign Prostatic Hyperplasia Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Benign Prostatic Hyperplasia treatment therapies with a considerable amount of success over the years.

*
Benign Prostatic Hyperplasia companies working in the treatment market are AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics Inc, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Sophiris Bio Corp, Warner Chilcott, Nymox Corporation, QLT Inc., NeoTract, Inc., Xintian Pharmaceutical, and others, are developing therapies for the Benign Prostatic Hyperplasia treatment

*
Emerging Benign Prostatic Hyperplasia therapies in the different phases of clinical trials are- AIV007, CKD-846, DTT106, Paclitaxel, RT-310, Teverelix trifluoroacetate, Fexapotide, GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, NX-1207, QLT0074, Tamsulosin Hydrochloride, Ningmitai capsule, and others are expected to have a significant impact on the Benign Prostatic Hyperplasia market in the coming years.

*
In October 2023, Nymox Pharmaceutical Corporation has disclosed that their recent application for Fexapotide Triflutate, intended for addressing symptoms associated with benign prostate enlargement (commonly known as benign prostatic hyperplasia or BPH), has been officially recognized by the UK authorities, specifically the UK Medicines & Healthcare products Regulatory Agency (MHRA). The formal evaluation process is now underway. The product will be marketed under the trademarked name NYMOZARFEX. The Marketing Authorization Application (MAA) was lodged on September 25, 2023.

Benign Prostatic Hyperplasia Overview

Benign prostatic hyperplasia (BPH), also known as prostate gland enlargement, is a common condition that affects older men. The prostate gland, which is part of the male reproductive system, surrounds the urethra (the tube that carries urine from the bladder out of the body).

Get a Free Sample PDF Report to know more about Benign Prostatic Hyperplasia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-pipeline-insight [https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Benign Prostatic Hyperplasia Drugs Under Different Phases of Clinical Development Include:

*
AIV007: AiViva BioPharma

*
CKD-846: Chong Kun Dang

*
DTT106: EMS

*
Paclitaxel: Urotronic Inc.

*
RT-310: Resurge Therapeutics Inc

*
Teverelix trifluoroacetate: Antev

*
Fexapotide: Nymox Pharmaceutical

*
GI198745: GlaxoSmithKline

*
DKF-313: Dongkook Pharmaceutical

*
Silodosin: RECORDATI GROUP

*
ASP4901: Astellas Pharma Inc

*
Tadalafil: Eli Lilly and Company

*
PRX302: Sophiris Bio Corp

*
Levitra (Vardenafil, BAY38-9456): Bayer

*
PRX302: Sophiris Bio Corp

*
WC3055: Warner Chilcott

*
NX-1207: Nymox Corporation

*
QLT0074: QLT Inc.

*
Tamsulosin Hydrochloride: NeoTract, Inc.

*
Ningmitai capsule: Xintian Pharmaceutical

Benign Prostatic Hyperplasia Route of Administration

Benign Prostatic Hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Benign Prostatic Hyperplasia Molecule Type

Benign Prostatic Hyperplasia Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Benign Prostatic Hyperplasia Pipeline Therapeutics Assessment

*
Benign Prostatic Hyperplasia Assessment by Product Type

*
Benign Prostatic Hyperplasia By Stage and Product Type

*
Benign Prostatic Hyperplasia Assessment by Route of Administration

*
Benign Prostatic Hyperplasia By Stage and Route of Administration

*
Benign Prostatic Hyperplasia Assessment by Molecule Type

*
Benign Prostatic Hyperplasia by Stage and Molecule Type

DelveInsight's Benign Prostatic Hyperplasia Report covers around 5+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Benign Prostatic Hyperplasia product details are provided in the report. Download the Benign Prostatic Hyperplasia pipeline report to learn more about the emerging Benign Prostatic Hyperplasia therapies [https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Benign Prostatic Hyperplasia Therapeutics Market include:

Key companies developing therapies for Benign Prostatic Hyperplasia are - Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Allergan PLC, Astellas Pharma Inc., and others.

Benign Prostatic Hyperplasia Pipeline Analysis:

The Benign Prostatic Hyperplasia pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Benign Prostatic Hyperplasia with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Benign Prostatic Hyperplasia Treatment.

*
Benign Prostatic Hyperplasia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Benign Prostatic Hyperplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Benign Prostatic Hyperplasia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Benign Prostatic Hyperplasia drugs and therapies [https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Benign Prostatic Hyperplasia Pipeline Market Drivers

*
The prevalence of this disease drives demand for treatments, creating a growth opportunity for pharmaceutical companies and medical device manufacturers in the BPH market thus fuels research, development, and innovation, leading to the introduction of new therapies and technologies.

Benign Prostatic Hyperplasia Pipeline Market Barriers

*
The presence of significant side effects linked to BPH treatments can deter patient adherence and acceptance, limiting market expansion as concerns about safety and tolerability affect physician prescribing patterns and hinder uptake of therapies

Scope of Benign Prostatic Hyperplasia Pipeline Drug Insight

*
Coverage: Global

*
Key Benign Prostatic Hyperplasia Companies: AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics Inc, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Sophiris Bio Corp, Warner Chilcott, Nymox Corporation, QLT Inc., NeoTract, Inc., Xintian Pharmaceutical, and others

*
Key Benign Prostatic Hyperplasia Therapies: AIV007, CKD-846, DTT106, Paclitaxel, RT-310, Teverelix trifluoroacetate, Fexapotide, GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, NX-1207, QLT0074, Tamsulosin Hydrochloride, Ningmitai capsule, and others

*
Benign Prostatic Hyperplasia Therapeutic Assessment: Benign Prostatic Hyperplasia current marketed and Benign Prostatic Hyperplasia emerging therapies

*
Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia market drivers and Benign Prostatic Hyperplasia market barriers

Request for Sample PDF Report for Benign Prostatic Hyperplasia Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Benign Prostatic Hyperplasia Report Introduction

2. Benign Prostatic Hyperplasia Executive Summary

3. Benign Prostatic Hyperplasia Overview

4. Benign Prostatic Hyperplasia- Analytical Perspective In-depth Commercial Assessment

5. Benign Prostatic Hyperplasia Pipeline Therapeutics

6. Benign Prostatic Hyperplasia Late Stage Products (Phase II/III)

7. Benign Prostatic Hyperplasia Mid Stage Products (Phase II)

8. Benign Prostatic Hyperplasia Early Stage Products (Phase I)

9. Benign Prostatic Hyperplasia Preclinical Stage Products

10. Benign Prostatic Hyperplasia Therapeutics Assessment

11. Benign Prostatic Hyperplasia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Benign Prostatic Hyperplasia Key Companies

14. Benign Prostatic Hyperplasia Key Products

15. Benign Prostatic Hyperplasia Unmet Needs

16 . Benign Prostatic Hyperplasia Market Drivers and Barriers

17. Benign Prostatic Hyperplasia Future Perspectives and Conclusion

18. Benign Prostatic Hyperplasia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=benign-prostatic-hyperplasia-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-boehringer-ingelheim-merck-co-inc-allergan-plc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.